HDAC inhibitors for the treatment of diabetic peripheral neuropathy

Patent metadata

Field	Value
Publication number	US-10040769-B2
Application number	US-201615335971-A
Country	US
Kind code	B2
Filing date	Oct 27, 2016
Priority date	Oct 27, 2015
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.

First claim

The invention claimed is:

1. A method for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC6-specific inhibitor, wherein the HDAC6-specific inhibitor is:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the HDAC6-specific inhibitor is administered by oral administration.

Assignees

• Acetylon Pharmaceuticals Inc
• Regenacy Pharmaceuticals Llc

Inventors

• Golonzhka Olga
• Jarpe Matthew B

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61K31/164

  of a carboxylic acid with an aminoalcohol, e.g. ceramides · CPC title

• A61K31/495

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title